Compare Aecom (ACM) vs Novavax Inc (NVAX) Price & Performance

ACM's stock trades at $63.61, down 5.13% amid a bearish technical outlook and mixed earnings, including a Q2 2026 loss of $0.50 per share versus a $1.46 estimate. Revenue growth has been volatile, with 2025 revenue at $16.14 billion and net income of $561.77 million, but profitability metrics like ROE of -3.89% and net margin of 1.87% indicate challenges. Recent news highlights a securities fraud investigation and a $337 million pre-tax charge from project delays, offset by a new Lisbon Airport design win.

The stock faces headwinds from weak technical signals and earnings misses, but analyst consensus remains bullish with a $83.17 price target, suggesting 31% upside. Risks include legal scrutiny, execution delays, and margin pressure, while institutional holdings and backlog growth offer stability. Investors should weigh the high analyst optimism against fundamental weaknesses and ongoing volatility.

Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.

The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.